IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 1 biotech developing next-gen CAR-T therapies for blood cancers.
Industry: Health Care
Latest Trade: $53.42 -1.02 (-1.9%)
First Day Return: +12.0%
Return from IPO: +262.9%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/14/2022 |
Offer Price | $15.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 8.3 |
Deal Size ($mm) | $124 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 02/03/2022 |
Offer Price | $15.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 8.3 |
Deal Size ($mm) | $124 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
BofA Securities |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Gaithersburg, MD, United States |
Founded | 2014 |
Employees | 78 |
Website www.arcellx.com |